Onxeo
Developing precision-guided therapeutics using small antibodies for complex diseases.
ALONX | PA
Overview
Corporate Details
- ISIN(s):
- FR0010095596 (+3 more)
- LEI:
- 96950018AS30IUG0V528
- Country:
- France
- Address:
- 49 BOULEVARD DU GENERAL MARTIAL VALIN, 75015 PARIS
- Website:
- https://www.onxeo.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Valerio Therapeutics, formerly known as Onxeo, is a clinical-stage biotechnology company pioneering next-generation precision-guided therapeutics. The company's core is its proprietary V-Body platform, which utilizes fully synthetic, ultra-small single-domain antibodies (sdAbs) to achieve deep tissue penetration and highly precise therapeutic delivery. This technology is applied to develop treatments for complex and underserved diseases. Valerio Therapeutics' strategy involves advancing its therapeutic candidates to key preclinical and clinical milestones before establishing strategic partnerships for co-development, out-licensing, and collaborative R&D to bring its innovations to patients.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Onxeo and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-06 17:06 |
Report Publication Announcement
Inside Information / Other news releases
|
English | 245.0 KB | |
| 2025-05-06 17:06 |
Report Publication Announcement
Informations privilégiées / Autres communiqués
|
French | 247.1 KB | |
| 2025-03-19 15:27 |
Board/Management Information
Inside Information / Other news releases
|
English | 146.6 KB | |
| 2025-03-19 12:30 |
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
|
French | 192.3 KB | |
| 2025-03-19 12:30 |
Pre-Annual General Meeting Information
Inside Information / Other news releases
|
English | 257.6 KB | |
| 2025-03-03 17:35 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 274.6 KB | |
| 2025-03-03 17:35 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 207.6 KB | |
| 2024-11-15 08:00 |
Board/Management Information
Inside Information / Other news releases
|
English | 132.0 KB | |
| 2024-11-15 08:00 |
Board/Management Information
Informations privilégiées / Autres communiqués
|
French | 194.5 KB | |
| 2024-09-30 22:40 |
Interim Report
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier …
|
French | 1.7 MB | |
| 2024-09-30 22:40 |
Interim Report
Half yearly financial reports and audit reports/limited reviews / Half yearly f…
|
English | 2.1 MB | |
| 2024-09-30 22:40 |
Earnings Release
Inside Information: News release on accounts, results
|
English | 387.9 KB | |
| 2024-09-30 22:40 |
Interim Report
Inside Information: News release on accounts, results
|
French | 373.1 KB | |
| 2024-09-30 07:00 |
M&A Activity
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
|
French | 213.4 KB | |
| 2024-09-30 07:00 |
M&A Activity
Inside Information / Operations of the issuer (acquisitions, sales...)
|
English | 276.8 KB |
Automate Your Workflow. Get a real-time feed of all Onxeo filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Onxeo via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-09 | N/A | Other | Other | 17,857,143 | 5,000,000.04 EUR |
| 2023-06-09 | N/A | Other | Other | 7,142,857 | 1,999,999.96 EUR |
